Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Clinical effectiveness and safety of escitalopram and desvenlafaxine in patients of depression with anxiety: a randomized, open-label controlled trial.

Maity N, Ghosal MK, Gupta A, Sil A, Chakraborty S, Chatterjee S.

Indian J Pharmacol. 2014 Jul-Aug;46(4):433-7. doi: 10.4103/0253-7613.135959.

2.

Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.

Soares CN, Thase ME, Clayton A, Guico-Pabia CJ, Focht K, Jiang Q, Kornstein SG, Ninan PT, Kane CP.

CNS Drugs. 2011 Mar;25(3):227-38. doi: 10.2165/11586460-000000000-00000.

PMID:
21323394
3.
4.

Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder.

Soares CN, Thase ME, Clayton A, Guico-Pabia CJ, Focht K, Jiang Q, Kornstein SG, Ninan P, Kane CP, Cohen LS.

Menopause. 2010 Jul;17(4):700-11. doi: 10.1097/gme.0b013e3181d88962.

PMID:
20539246
5.

Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.

Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ.

Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. Review.

PMID:
19919295
6.

The effect of desvenlafaxine 50 mg/day on a subpopulation of anxious/depressed patients: a pooled analysis of seven randomized, placebo-controlled studies.

Kornstein SG, Guico-Pabia CJ, Fayyad RS.

Hum Psychopharmacol. 2014 Sep;29(5):492-501. doi: 10.1002/hup.2427. Epub 2014 Aug 11.

PMID:
25196042
7.

Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.

Lam RW, Lönn SL, Despiégel N.

Int Clin Psychopharmacol. 2010 Jul;25(4):199-203. doi: 10.1097/YIC.0b013e32833948d8.

PMID:
20357664
8.
9.
10.

A double-blind, randomized, placebo-controlled study assessing the efficacy and tolerability of desvenlafaxine 10 and 50 mg/day in adult outpatients with major depressive disorder.

Liebowitz MR, Tourian KA, Hwang E, Mele L; Study 3362 Investigators.

BMC Psychiatry. 2013 Mar 22;13:94. doi: 10.1186/1471-244X-13-94.

11.

A pooled analysis of the efficacy of desvenlafaxine for the treatment of major depressive disorder in perimenopausal and postmenopausal women.

Kornstein SG, Clayton AH, Bao W, Guico-Pabia CJ.

J Womens Health (Larchmt). 2015 Apr;24(4):281-90. doi: 10.1089/jwh.2014.4900.

PMID:
25860107
12.

Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder.

Liebowitz MR, Manley AL, Padmanabhan SK, Ganguly R, Tummala R, Tourian KA.

Curr Med Res Opin. 2008 Jul;24(7):1877-90. doi: 10.1185/03007990802161923 . Epub 2008 May 27.

PMID:
18507895
14.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
15.

Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo.

Dunlop BW, Reddy S, Yang L, Lubaczewski S, Focht K, Guico-Pabia CJ.

J Clin Psychopharmacol. 2011 Oct;31(5):569-76. doi: 10.1097/JCP.0b013e31822c0a68.

PMID:
21869698
16.

Efficacy and safety of desvenlafaxine 25 and 50▒mg/day in a randomized, placebo-controlled study of depressed outpatients.

Iwata N, Tourian KA, Hwang E, Mele L, Vialet C.

J Psychiatr Pract. 2013 Jan;19(1):5-14. doi: 10.1097/01.pra.0000426323.59698.64.

PMID:
23334675
17.

Pilot study of augmentation with aripiprazole for incomplete response in late-life depression: getting to remission.

Sheffrin M, Driscoll HC, Lenze EJ, Mulsant BH, Pollock BG, Miller MD, Butters MA, Dew MA, Reynolds CF 3rd.

J Clin Psychiatry. 2009 Feb;70(2):208-13. Epub 2009 Feb 10.

18.

Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder:a randomized controlled trial.

Rosenthal JZ, Boyer P, Vialet C, Hwang E, Tourian KA.

J Clin Psychiatry. 2013 Feb;74(2):158-66. doi: 10.4088/JCP.12m07974.

PMID:
23473348
19.

Efficacy of desvenlafaxine 50 mg compared with placebo in patients with moderate or severe major depressive disorder: a pooled analysis of six randomized, double-blind, placebo-controlled studies.

Papakostas GI, Culpepper L, Fayyad RS, Musgnung J, Guico-Pabia CJ.

Int Clin Psychopharmacol. 2013 Nov;28(6):312-21. doi: 10.1097/YIC.0b013e3283638fbd.

PMID:
23881185
20.

Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial.

Mohamed S, Osatuke K, Aslam M, Kasckow J.

Am J Geriatr Pharmacother. 2006 Sep;4(3):201-9.

PMID:
17062320

Supplemental Content

Support Center